glp-1 receptor agonist blood pressure reduction Agonists as Treatments for Type 2 Diabetes Cardiovascular Effects of Glucagon-Like Peptide-1

The Alberta Blue Cross report notes that several notable generic medications and biosimilars under Health Canada review could provide significant cost savings for plan sponsors, though the insurer's overall view is that GLP-1 category spend will remain elevated as utilization broadens [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]

Without safety data, the assumption has to swing toward caution, and that shapes how peptides get handled across the pregnancy window

Best of all, our products are scientifically proven and trusted

doi: 10.1210/endo.139.3.5832 97 WebsterNJResnikJLReichartDBStraussBHaasMSeelyBL